UPDATE 1-FDA panel votes against Novartis drug for acute heart failure Reuters UK Novartis filed for approval of the drug, serelaxin, based on a single study that showed that when given alongside standard treatment, it alleviated shortness of breath by slowing the rate of worsening heart failure following hospitalization. Panelists ... |
